newsfilter
← Latest News
GlobeNewswire·

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

Top line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple